TRIUMPH-1 & TRANSCEND-T2D-1: Retatrutide Phase 3 Data Explained

Cardiometabolic Secondary Endpoints

Beyond weight reduction, TRIUMPH-1 reported statistically significant improvements in waist circumference, systolic blood pressure, fasting triglycerides, and high-density lipoprotein cholesterol. These cardiometabolic markers are clinically relevant given the established relationship between central adiposity and cardiovascular risk, though formal cardiovascular outcomes data from a dedicated CVOT trial have not yet been published for retatrutide.

---

TRANSCEND-T2D-1: Glycemic Efficacy in Type 2 Diabetes

Methodology

TRANSCEND-T2D-1 enrolled adults with type 2 diabetes (T2D) and overweight or obesity, evaluating retatrutide against placebo and, in some arms, an active comparator. The primary endpoints included change in HbA1c from baseline and percentage change in body weight at week 48. The inclusion of an active comparator arm allows for head-to-head contextualization within the incretin drug class.

Glycemic and Weight Outcomes

TRANSCEND-T2D-1 demonstrated that retatrutide produced substantial HbA1c reductions—consistent with or exceeding those reported for tirzepatide in the SURPASS program—alongside body weight reductions that approached, though did not fully replicate, the magnitude seen in TRIUMPH-1's non-diabetic cohort. This pattern is consistent with prior incretin pharmacology: the physiological ceiling for weight loss is somewhat attenuated in individuals with T2D relative to those without, likely due to differences in beta-cell function, insulin resistance, and baseline metabolic state.

The glucagon receptor agonism component of retatrutide's mechanism raised a priori concerns about glycemic safety; however, TRANSCEND-T2D-1 data indicate that the net glycemic effect is antidiabetic when GIP and GLP-1 co-agonism is present, consistent with preclinical modeling and the earlier Phase 2 data published by Jastreboff et al. in *Obesity* (2023).

---

The Dysesthesia Safety Signal: What Researchers Need to Know

Definition and Clinical Presentation

Dysesthesia—defined as an abnormal, often unpleasant sensation (burning, tingling, or electric shock-like feelings) arising without an identifiable external stimulus—emerged as a statistically notable adverse event in both TRIUMPH-1 and TRANSCEND-T2D-1. This signal was not prominently reported in the earlier Phase 2 retatrutide trial (Jastreboff et al., *New England Journal of Medicine*, 2023; DOI: 10.1056/NEJMoa2301972), suggesting either a dose-dependent phenomenon, a duration-dependent phenomenon, or an artifact of larger sample size enabling detection of a rarer event.

Mechanistic Hypotheses

Several mechanistic hypotheses are under consideration in the research community:

• **Glucagon receptor expression in peripheral sensory neurons**: GCGR has been identified in dorsal root ganglia in preclinical models, raising the possibility that sustained glucagon receptor agonism may modulate peripheral sensory neuron excitability.
• **Rapid adipose tissue remodeling**: The speed and magnitude of fat loss with retatrutide may alter the mechanical and biochemical microenvironment of peripheral nerves embedded in adipose tissue.
• **GLP-1 receptor-mediated nociceptive modulation**: GLP-1 receptors are expressed in peripheral sensory and autonomic neurons; their sustained agonism at high doses may alter sensory thresholds.

At this stage, the mechanistic basis of retatrutide-associated dysesthesia remains unresolved. Researchers should note that the majority of reported cases in the trial data were characterized as mild-to-moderate in severity and did not consistently lead to treatment discontinuation, though the long-term implications for peripheral nerve integrity require prospective evaluation.

---

Comparative Context: How Does Retatrutide Stack Up?

| Agent | Mechanism | Peak Phase 3 Weight Loss | Trial | |---|---|---|---| | Semaglutide 2.4 mg | GLP-1 RA | ~14.9% | STEP 1 (Wilding et al., NEJM 2021) | | Tirzepatide 15 mg | GIP/GLP-1 dual | ~22.5% | SURMOUNT-1 (Jastreboff et al., NEJM 2022) | | Retatrutide (high dose) | GIP/GLP-1/GCGR triple | >30% (reported) | TRIUMPH-1 (2025–2026) |

This trajectory suggests that incremental receptor targets within the incretin/glucagon axis continue to yield additive efficacy, though whether this relationship is linear, asymptotic, or subject to individual pharmacogenomic variation remains an open research question.

---

Regulatory and Research Implications

Eli Lilly has indicated plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration based on the TRIUMPH and TRANSCEND program data. The dysesthesia signal will require detailed characterization in the NDA safety package, and regulators may request additional neurological follow-up data or a post-marketing commitment study.

For the research community, TRIUMPH-1 and TRANSCEND-T2D-1 collectively establish retatrutide as the benchmark against which future obesity pharmacotherapies will be measured. The mechanistic question of how glucagon receptor co-agonism contributes to weight loss without net hyperglycemia in the context of GIP/GLP-1 co-stimulation remains a productive area for translational investigation.

---

Limitations and What Remains Unknown

• Full peer-reviewed manuscripts for both TRIUMPH-1 and TRANSCEND-T2D-1 were not available in final published form at the time of this summary; some data points reflect top-line press releases and conference presentations, which are subject to revision upon full publication.
• Long-term cardiovascular outcomes data (CVOT) for retatrutide are not yet available.
• The durability of weight loss beyond 48 weeks and the trajectory of weight regain upon discontinuation have not been reported from Phase 3 data.
• The dysesthesia mechanism requires dedicated mechanistic studies; current hypotheses are speculative.

Researchers are encouraged to consult the primary publications upon their release in peer-reviewed journals for complete statistical methodology, subgroup analyses, and safety adjudication data.